ArticleScientific reports2017
A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Blood and CSF chemokines in Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis.Alzheimer's research & therapy · 2023Pooled it
- A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer's Disease?Dermatology and therapy · 2026Review
- Tracing neuroinflammation in neurodegeneration: insights from a scoping review on biofluid biomarkers.Brain communications · 2026Review
- Brain interleukins and Alzheimer's disease.Metabolic brain disease · 2025Review
- Association of preoperative to postoperative change in cerebrospinal fluid fibrinogen with postoperative delirium.BJA open · 2024Article
- Evaluation of serum interleukin-12 and interleukin-4 as potential biomarkers for the diagnosis of major depressive disorder.Scientific reports · 2024Article
- Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond.Current neuropharmacology · 2024Article
- Targeting neuroinflammation in Alzheimer's disease: from mechanisms to clinical applications.Neural regeneration research · 2023Review
- Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment.Journal of nanobiotechnology · 2023Article
- Graphene-Based Biosensors for Molecular Chronic Inflammatory Disease Biomarker Detection.Biosensors · 2022Review
- Pharmacological Management of Apathy in Dementia.CNS drugs · 2022Review
- Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review.Frontiers in aging neuroscience · 2022Article
- Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease.Journal of Alzheimer's disease reports · 2021Article
- Microglia-Derived Interleukin 23: A Crucial Cytokine in Alzheimer's Disease?Frontiers in neurology · 2021Review
- The role of innate immunity in Alzheimer's disease.Immunological reviews · 2020Review
- Blood-based protein predictors of dementia severity as measured by δ: Replication across biofluids and cohorts.Alzheimer's & dementia (Amsterdam, Netherlands) · 2019Article
- Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease.Acta neuropathologica communications · 2019Article
- Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies.Journal of Alzheimer's disease : JAD · 2018Review
- The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization.Alzheimer's & dementia (New York, N. Y.)Review
- Associations between systemic inflammatory markers and cognitive decline in patients with early-stage Alzheimer's disease: a retrospective clinical study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 12 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's Disease (AD) is the most common form of dementia, characterised by extracellular amyloid deposition as plaques and intracellular neurofibrillary tangles of tau protein. As no current clinical test can diagnose individuals at risk of developing AD, the aim of this project is to evaluate a blood-based biomarker panel to identify individuals who carry this risk. We analysed the levels of 22 biomarkers in clinically classified healthy controls (HC), mild cognitive impairment (MCI) and Alzheimer's participants from the well characterised Australian Imaging, Biomarker and Lifestyle (AIBL) study of aging. High levels of IL-10 and IL-12/23p40 were significantly associated with amyloid deposition in HC, suggesting that these two biomarkers might be used to detect at risk individuals. Additionally, other biomarkers (Eotaxin-3, Leptin, PYY) exhibited altered levels in AD participants possessing the APOE ε4 allele. This suggests that the physiology of some potential biomarkers may be altered in AD due to the APOE ε4 allele, a major risk factor for AD. Taken together, these data highlight several potential biomarkers that can be used in a blood-based panel to allow earlier identification of individuals at risk of developing AD and/or early stage AD for which current therapies may be more beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.